...
首页> 外文期刊>Clinical and translational science. >Translational Development of Microbiome-Based Therapeutics: Kinetics of E-coli Nissle and Engineered Strains in Humans and Nonhuman Primates
【24h】

Translational Development of Microbiome-Based Therapeutics: Kinetics of E-coli Nissle and Engineered Strains in Humans and Nonhuman Primates

机译:基于微生物组的治疗方法的翻译发展:人类和非人类和非人类和非人类和非人类灵长类动物电子大肠杆菌和工程菌株的动力学

获取原文
获取原文并翻译 | 示例
           

摘要

Understanding the pharmacology of microbiome-based therapeutics is required to support the development of new medicines. Strains of E. coli Nissle (EcN) were genetically modified and administered to cynomolgus monkeys at doses of 1 x 10(9) and 1 x 10(12) colony-forming units (CFU)/day for 28 days. A clinical study to evaluate the exposure and clearance of EcN in healthy volunteers was also performed. Healthy subjects received oral doses of EcN, 2.5 to 25 x 10(9) CFU 3times daily for 28 days or a single day. In cynomolgus monkeys, replicating strains yielded higher fecal concentrations than nonreplicating strains and persisted for longer following cessation of dosing. In the clinical study, all subjects cleared EcN following cessation of dosing with median clearance of 1 week. Quantitative methodology can be applied to microbiome-based therapeutics, and similar kinetics and clearance were observed for EcN in cynomolgus monkeys and humans.
机译:理解基于微生物组的治疗剂的药理学,需要支持新药的发展。 大肠杆菌烟头(ECN)的菌株被遗传修饰,并以1×10(9)和1×10(12)个菌落 - 形成单位(CFU)/日为28天的剂量给药猴子。 还进行了评估健康志愿者ECN暴露和间隙的临床研究。 健康受试者每天28天或一天收到口服剂量的ECN,2.5至25 x 10(9)CFU 3次。 在Cynomolgus猴子中,复制菌株比不重种菌株产生较高的粪便浓度,并且在停止给药后持续长度。 在临床研究中,所有受试者在停止给药后,所有受试者都会清除1周的中位清除。 定量方法可以应用于基于微生物组的治疗方法,并且在Cynomolgus猴子和人类中的ECN观察到类似的动力学和间隙。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号